Intelligent Bio Solutions Launches Codeine Screening Clinical Program

Intelligent Bio Solutions ( (INBS) ) has issued an announcement.

On January 28, 2026, Intelligent Bio Solutions announced it has begun a new clinical study program to support an FDA 510(k) submission for U.S. market clearance of its non-invasive Intelligent Fingerprinting Drug Screening System for detecting the opiate codeine. Working with clinical research organization Cliantha Research, the company is running an initial study in 40 adults using its cartridge and DSR-Plus reader, comparing performance with an existing FDA-cleared predicate device and confirming results via LC-MS/MS, with the first cohort starting the same day and full data analysis expected by the end of March 2026. The resulting data will be folded into an FDA submission aimed at moving the product beyond “Forensic Use Only” status and into broader U.S. commercial use, positioning the company to tap into the multi-billion-dollar U.S. drug screening market and potentially strengthening its competitive standing in workplace, clinical, and law-enforcement testing segments.

The most recent analyst rating on (INBS) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.

Spark’s Take on INBS Stock

According to Spark, TipRanks’ AI Analyst, INBS is a Neutral.

The score is held back primarily by severe operating losses and substantial ongoing cash burn despite improving revenue and a low-debt balance sheet. Offsetting this, corporate events (Nasdaq compliance, new financing, and a cost-saving manufacturing partnership) improve near-term survivability and potential margins, while technicals are mixed/neutral and valuation remains constrained by unprofitability.

To see Spark’s full report on INBS stock, click here.

More about Intelligent Bio Solutions

Intelligent Bio Solutions Inc. is a medical technology company that develops intelligent, rapid, non-invasive testing solutions, centered on its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat. The system is designed as a hygienic, cost-effective alternative to urine, oral fluid, and blood tests, screening for recent use of drugs such as opiates, cocaine, methamphetamine, and cannabis, and is currently used outside the U.S. by customers in construction, manufacturing and engineering, transport and logistics, mining, drug treatment organizations, and coroners, particularly in safety-critical workplace settings.

Average Trading Volume: 2,391,220

Technical Sentiment Signal: Sell

Current Market Cap: $11.05M

See more insights into INBS stock on TipRanks’ Stock Analysis page.